Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for proliferative diabetic retinopathy with diabetic macular edema
jRCTs031180307Completed
- Sponsor
- Bayer
- Start
- Aug 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of aflibercept in diabetic retinopathy (DR) and diabetic macular edema (DME), sponsored by Bayer. Primary endpoint: Change of non-perfusion area. Started Aug 2018; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic retinopathy (DR)diabetic macular edema (DME)
Beyond the preview
Go deeper on jRCTs031180307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180307.